Similar articles for PMID: 34601977

Year	Number of Results
1995	1
2000	1
2003	2
2004	2
2005	1
2008	2
2010	3
2011	4
2012	6
2013	3
2014	4
2015	10
2016	13
2017	10
2018	18
2019	13
2020	12
2021	8
2022	6
2023	2
2024	0

1

Emerging drugs for hemophilia A: insights into phase II and III clinical trials.

Kizilocak H, Young G. Kizilocak H, et al. Expert Opin Emerg Drugs. 2021 Dec;26(4):337-350. doi: 10.1080/14728214.2021.1988073. Epub 2021 Oct 11. Expert Opin Emerg Drugs. 2021. PMID: 34601977 Review.

2

Prophylaxis for hemophilia A without inhibitors: treatment options and considerations.

Valentino LA, Khair K. Valentino LA, et al. Expert Rev Hematol. 2020 Jul;13(7):731-743. doi: 10.1080/17474086.2020.1775576. Epub 2020 Jun 23. Expert Rev Hematol. 2020. PMID: 32573295 Review.

3

An update of the current pharmacotherapeutic armamentarium for hemophilia A.

Mahlangu J. Mahlangu J. Expert Opin Pharmacother. 2022 Jan;23(1):129-138. doi: 10.1080/14656566.2021.1961742. Epub 2021 Aug 18. Expert Opin Pharmacother. 2022. PMID: 34404300

4

Efmoroctocog Alfa: A Review in Haemophilia A.

Frampton JE. Frampton JE. Drugs. 2021 Nov;81(17):2035-2046. doi: 10.1007/s40265-021-01615-w. Epub 2021 Nov 7. Drugs. 2021. PMID: 34743314 Free PMC article. Review.

5

Efficacy and safety of a recombinant factor VIII produced from a human cell line (simoctocog alfa).

Franchini M, Mannucci PM. Franchini M, et al. Expert Opin Drug Saf. 2017 Mar;16(3):405-410. doi: 10.1080/14740338.2017.1285281. Epub 2017 Feb 1. Expert Opin Drug Saf. 2017. PMID: 28103444 Review.

6

Recombinant B domain deleted porcine factor VIII for the treatment of bleeding episodes in adults with acquired hemophilia A.

Gomperts E. Gomperts E. Expert Rev Hematol. 2015 Aug;8(4):427-32. doi: 10.1586/17474086.2015.1040758. Epub 2015 Apr 30. Expert Rev Hematol. 2015. PMID: 25927594 Review.

7

Turoctocog alfa for the treatment of hemophilia A.

Haddley K. Haddley K. Drugs Today (Barc). 2014 Feb;50(2):121-31. doi: 10.1358/dot.2014.50.2.2116671. Drugs Today (Barc). 2014. PMID: 24619589 Review.

8

OBI-1, porcine recombinant Factor VIII for the potential treatment of patients with congenital hemophilia A and alloantibodies against human Factor VIII.

Toschi V. Toschi V. Curr Opin Mol Ther. 2010 Oct;12(5):617-25. Curr Opin Mol Ther. 2010. PMID: 20886394

9

Half-life extended factor VIII for the treatment of hemophilia A.

Tiede A. Tiede A. J Thromb Haemost. 2015 Jun;13 Suppl 1:S176-9. doi: 10.1111/jth.12929. J Thromb Haemost. 2015. PMID: 26149020 Free article. Review.

10

Emicizumab for hemophilia A with factor VIII inhibitors.

Young G, Callaghan M, Dunn A, Kruse-Jarres R, Pipe S. Young G, et al. Expert Rev Hematol. 2018 Nov;11(11):835-846. doi: 10.1080/17474086.2018.1531701. Epub 2018 Oct 10. Expert Rev Hematol. 2018. PMID: 30278802 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

108 results

Results by year